FOUNDATIONONE®LIQUID CDx

PATIENT
Liu, Hai-Yun

TUMOR TYPE
Lung adenocarcinoma
COUNTRY CODE
TW

REPORT DATE
23 Jan 2022
ORDERED TEST #
ORD-1279363-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Lung adenocarcinoma
NAME Liu, Hai-Yun
DATE OF BIRTH 14 July 1957
SEX Male
MEDICAL RECORD # 43272544

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID H-YL 7/14/1957
SPECIMEN TYPE Blood
DATE OF COLLECTION 11 January 2022
SPECIMEN RECEIVED 14 January 2022

Biomarker Findings

Blood Tumor Mutational Burden - 38 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

EGFR L858R
ASXL1 G646fs*12
BCL2L1 amplification
CIC S950*, rearrangement intron 11, inversion exons 9-11, POTEA-CIC rearrangement
CREBBP E1012K
MSH6 S321*
NFE2L2 D77H
RBM10 A184fs*80
TP53 R158fs*12

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Afatinib** (p. 12), **Dacomitinib** (p. 14), **Erlotinib** (p. 16), **Gefitinib** (p. 17), **Osimertinib** (p. 19)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 22)
- Variants that may represent **clonal hematopoiesis** and may originate from non-tumor sources: ***ASXL1*** **G646fs*12** (p. 6)

BIOMARKER FINDINGS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
Blood Tumor Mutational Burden - 38 Muts/Mb	Atezolizumab	Avelumab
	Cemiplimab	
	Dostarlimab	
	Durvalumab	
	Nivolumab	
	Pembrolizumab	
10 Trials see p. 22		
Microsatellite status - MSI-High Not Detected	**MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).**	
Tumor Fraction - Elevated Tumor Fraction	**Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. There is higher sensitivity for identifying genomic alterations and a lower risk of false negative results in specimens with elevated tumor fraction; the positive percent agreement observed between liquid and tissue for defined short variants is ≥ 90% (Li et al., 2021; AACR Abstract 2231) (see Biomarker Findings section).**	

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS		VAF %
EGFR -	L858R	8.1%

10 Trials see p. 24

THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	
Afatinib	1
Dacomitinib	1
Erlotinib	1
Gefitinib	1
Osimertinib	1

THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
None

1 *NCCN category*

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS (CH)

Genomic findings below may include nontumor somatic alterations, such as CH. The efficacy of targeting such nontumor somatic alterations is unknown. This content should be interpreted based on clinical context. Refer to appendix for additional information on CH.

ASXL1 - G646fs*12 ..... p. 6

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531



HISTORIC PATIENT FINDINGS		ORD-1279363-01 VAF%
Blood Tumor Mutational Burden		38 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		25%
EGFR	L858R	8.1%
ASXL1	G646fs*12	1.6%
BCL2L1	amplification	Detected
CIC	S950*	10.9%
	rearrangement intron 11	38.1%
	inversion exons 9-11	6.9%
	POTEA-CIC rearrangement	5.7%
CREBBP	E1012K	8.3%
MSH6	S321*	5.7%
NFE2L2	D77H	10.0%

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

HISTORIC PATIENT FINDINGS		ORD-1279363-01 VAF%
RBM10	A184fs*80	26.8%
TP53	R158fs*12	20.6%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT

38 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-2] and anti-PD-1[3] therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb[1]. In HNSCC, a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[4].

FREQUENCY & PROGNOSIS

NSCLC harbors a median bTMB of 16.8 Muts/Mb (range 1.9-52.5 Muts/Mb)[3]. Retrospective analysis of the Phase 3 OAK and Phase 2 POPLAR trials for patients with advanced or metastatic non-small cell lung cancer (NSCLC) reported that bTMB ≥7 Muts/Mb was associated with shorter PFS (2.8 vs. 4.2 months) and OS (7.4 vs. 11.9 months) compared with bTMB <7 Muts/Mb for patients treated with docetaxel[5]. In one study of advanced NSCLC in China, bTMB ≥6 Muts/Mb was associated with decreased PFS (10 vs. 18 months) and OS (11 vs. 25 months) compared with bTMB <6 Muts/Mb for patients treated with platinum-based chemotherapy[6]. A large study of Chinese patients with lung adenocarcinoma reported a shorter median OS for tumors with a higher number of mutations in a limited gene set compared with a lower mutation number (48.4 vs. 61.0 months)[7]. Another study of patients with NSCLC correlated elevated TMB with poorer prognosis and significantly associated lower TMB in combination with PD-L1 negative status with longer median survival in patients with lung adenocarcinoma[8]. However, no significant prognostic association of TMB and/or PD-L1 status with survival has been reported in patients with lung SCC[8-9].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[10-11] and cigarette smoke in lung cancer[12-13], treatment with temozolomide-based chemotherapy in glioma[14-15], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[16-20], and microsatellite instability (MSI)[16,19-20]. This sample harbors a bTMB level that may be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-3].

BIOMARKER

Tumor Fraction

RESULT

Elevated Tumor Fraction

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[21-26].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[27]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[28], Ewing sarcoma and osteosarcoma[29], prostate cancer[24], breast cancer[30], leiomyosarcoma[31], esophageal cancer[32], colorectal cancer[33], and gastrointestinal cancer[34].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[35], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[36-37].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
EGFR

ALTERATION
L858R

TRANSCRIPT ID
NM_005228

CODING SEQUENCE EFFECT
2573T>G

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

For patients with non-small cell lung cancer, EGFR activating mutations may predict sensitivity to EGFR TKIs, including erlotinib[38], gefitinib[39], afatinib[40], dacomitinib[41], and osimertinib[42]; however, the data for patients with other tumor types are limited[43-48]. The Phase 1 CHRYSALIS study of amivantamab monotherapy or in combination with lazertinib for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) has produced encouraging preliminary results for treatment-naive patients and patients who relapsed after treatment with osimertinib with and without chemotherapy, including osimertinib-relapsed patients with biomarkers indicating EGFR/MET-based osimertinib resistance[49-52] . In a Phase 1 trial, the HER3-targeted antibody patritumab deruxtecan elicited an ORR of 39% (22/57, 1 CR) and a median PFS of 8.2 months for patients with non-small cell lung cancer previously treated with an EGFR TKI, many of whom displayed TKI resistance alterations[53]. A Phase 1 trial evaluating the EGFR inhibitor AZD3759 reported a reduction in the volume of brain metastases in 40% (8/20) of patients with previously treated non-small cell lung cancer (NSCLC) harboring either the EGFR L858R alteration or EGFR exon 19 deletion, including 3 confirmed PRs and 3 unconfirmed PRs[54-55]. In a Phase 1/2 trial for advanced NSCLC, the brain-penetrant third-generation EGFR TKI lazertinib enabled ORRs of 54% (69/127) for all evaluable patients and 44% (8/18, intracranial) for patients with brain metastases[56]. The Phase 3 IMpower150 study showed that the addition of atezolizumab to bevacizumab plus chemotherapy treatment also had clinical efficacy for patients with EGFR-mutated or ALK-rearranged metastatic NSCLC[57]; therefore, the patient's clinical context should be considered.

FREQUENCY & PROGNOSIS

EGFR mutation has been reported in 12-36% of lung adenocarcinomas[58-60] and in 4% of lung squamous cell carcinomas[61]. EGFR protein expression/overexpression has been reported in up to 70% of NSCLC cases[62-67]. In addition, expression of EGFR protein has been shown to be higher in lung squamous cell carcinoma samples as compared to lung adenocarcinoma[68-69]. In patients with lung adenocarcinoma, EGFR mutation was a predictor of poor overall survival[70-71]. However, EGFR mutations have been reported to predict improved survival in patients with resected Stage 1-3 lung adenocarcinoma[72] or resected Stage 1 NSCLC[73].

FINDING SUMMARY

EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide[74]. EGFR L858 is located in the kinase domain and is encoded by exon 21. EGFR L858R has been characterized as activating[75-77] and patients with the L858R mutation have been shown to be sensitive to EGFR tyrosine kinase inhibitors, such as erlotinib, gefitinib[75-77], and afatinib[78].

GENE
ASXL1

ALTERATION
G646fs*12

TRANSCRIPT ID
NM_015338

CODING SEQUENCE EFFECT
1934_1935insG

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in ASXL1.

FREQUENCY & PROGNOSIS

ASXL1 alterations occur infrequently across various solid tumor types[79] and are not known to act as drivers in any specific solid cancer type[80]. Published data investigating the prognostic implications of ASXL1 alterations in solid tumors are limited (PubMed, May 2021). In the context of clonal hematopoiesis, ASXL1 mutations are significantly enriched in current or former smokers[81].

FINDING SUMMARY

ASXL1 regulates epigenetic marks and transcription through interaction with polycomb complex proteins and various transcription activators and repressors[82-84]. Alterations such as seen here may disrupt ASXL1 function or expression[85-87].

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[88-93]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[88-89]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[94]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[92,95-96]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
BCL2L1

ALTERATION
amplification

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies that target BCL2L1 amplification in cancer. Multiple investigational drugs that target BCL-2 family members including ABT-737, oblimersen sodium, AT-101, ABT-263 (navitoclax), and GX15-070 (obatoclax) are being studied in clinical trials[97]. Preclinical studies have shown activity of BCL-XL inhibitors in NSCLC cell lines and a xenograft mouse model[98-99]. Elevated BCL-XL levels protect cancer cells against apoptosis in multiple cancer types and may contribute to chemotherapy resistance[100-103].

FREQUENCY & PROGNOSIS

Gain of the 20q region where BCL2L1 is located has been reported in 34% of lung adenocarcinoma samples and in 75% of lung adenocarcinomas with EGFR mutations[104-105]. Expression of BCL-XL protein has been associated with poor prognosis in patients with ovarian cancer and has been reported to be associated with taxane resistance in colorectal cancer[106-110].

FINDING SUMMARY

BCL2L1 encodes BCL-XL, an anti-apoptotic member of the BCL-2 protein family that is frequently overexpressed in cancer[111]. In colorectal cancer, 20q gain has been associated with BCL-XL protein overexpression[112-114].

GENE
CIC

ALTERATION
S950*, rearrangement intron 11, inversion exons 9-11, POTEA-CIC rearrangement

TRANSCRIPT ID
NM_015125

CODING SEQUENCE EFFECT
2849C>G

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in CIC.

FREQUENCY & PROGNOSIS

CIC mutations have been described in various solid tumors, including 1–10% of sequenced gastric, endometrial, and colorectal carcinomas and melanoma tumors (cBioPortal, COSMIC, Jan 2022)[115-117], although the consequences of CIC mutations in these tumor types have not been studied. CIC mutations have been observed in 58–69% of oligodendrogliomas but are less common in other gliomas, such as astrocytoma or oligoastrocytoma[118-120]. Published data investigating the prognostic implications of CIC alterations are generally limited (PubMed, Jun 2021). Conflicting data have been reported regarding the prognostic significance of CIC mutation in oligodendroglioma[119,121-122].

FINDING SUMMARY

CIC encodes a transcriptional repressor that plays a role in central nervous system (CNS) development[123]. CIC inactivation has been reported in various malignancies, and is highly recurrent in oligodendroglioma[118-119].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE

CREBBP

ALTERATION
E1012K

TRANSCRIPT ID
NM_004380

CODING SEQUENCE EFFECT
3034G>A

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in CREBBP. The use of histone deacetylase (HDAC) inhibitors are being investigated in clinical trials that are recruiting patients with either lymphoma or urothelial carcinoma harboring CREBBP alterations. However, it has been reported that there is no correlation between CREBBP mutation status and response to HDAC inhibitors in DLBCL[124].

FREQUENCY & PROGNOSIS

CREBBP mutations have been observed at high frequency in follicular lymphoma (FL, 26%) and diffuse large B-cell lymphoma (DLBCL, 16%), and at lower frequency in acute lymphoblastic leukemia (ALL, 7%), and tumors of the urinary tract (15%), skin (12%), liver (9%), stomach (9%), and endometrium (8%)(COSMIC, 2022)[117]. These mutations include missense substitutions clustered in the CREBBP histone acetyltransferase domain and truncating mutations throughout the gene sequence, suggesting a role for CREBBP inactivation in these diseases. CREBBP mutations have been reported to occur in the transition from prostate acinar carcinoma to squamous cell carcinoma (SCC)[125], which may indicate significance for CREBBP in SCC. In two cases of relapsed pediatric B-cell ALL, CREBBP mutation conferred resistance to glucocorticoid therapy[126]. Reports have found CREBBP mutation in 62-68% of patients with FL[127-128], which was associated with immune evasion[127]. AML with MYST3/CREBBP fusion was reported to occur in 60-80% of cases 9-72 months after adjuvant chemotherapy for breast cancer and was associated with a poor prognosis[129-130].

FINDING SUMMARY

CREBBP encodes a ubiquitously expressed transcriptional coregulatory protein that interacts with multiple transcription factors and can couple control of gene expression to chromatin remodeling via its histone acetyltransferase activity. Inherited microdeletions and truncating point mutations in CREBBP are reported to be causal in approximately 20% of cases of Rubinstein-Taybi syndrome[131]. The chromosomal rearrangement t(8;16)(p11;p13) is characteristic of the M4/M5 subtype of acute myeloid leukemia (AML) and results in a chimeric gene fusing MYST3/MOZ (a gene essential for the development of the hematopoietic system and maintenance of hematopoietic stem cells) to CREBBP[132]. CREBBP-BCORL1 fusion has been reported in patients with ossifying fibromyxoid tumors[133-134].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
MSH6

ALTERATION
S321*

TRANSCRIPT ID
NM_000179

CODING SEQUENCE EFFECT
962C>A

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Numerous studies in various cancer types have shown that MSH6 loss or inactivation is associated with MSI and increased mutation burden[19,135-139]. Clinical studies have shown that MSI is associated with patient responses to anti-programmed death 1 (PD-1) immune checkpoint inhibitors pembrolizumab[140-141] and nivolumab[142]. Higher mutation burden was also reported to be associated with response to pembrolizumab[13]. Furthermore, MSI status correlates with higher PD-1 and PD-L1 expression[143], potential biomarkers of response to PD-1 targeted immunotherapies. Therefore, inactivation of MSH6 may confer sensitivity to anti-PD-1 immune checkpoint inhibitors.

FREQUENCY & PROGNOSIS

MSH6 mutation has been observed in 1.3% of lung adenocarcinomas[60] and in 2% of lung squamous cell carcinomas (SCCs)[61]. Although mutations in genes that serve to maintain genomic stability are generally found at low frequencies in sporadic cancers, mutations in MSH6 and DNA repair gene PRKDC have been identified in lung adenocarcinomas, and mutation rates were suggested to be influenced by defects in DNA repair genes (but not MSH6 specifically)[144-145]. Reports on the role of MSH6 mutations in prognosis have been conflicting. One study reported a correlation between reduced MMR gene mRNA and increased lymph node metastasis in patients with lung cancer, while other studies reported that MSH6 mutations may be a marker for MSI and may be associated with better prognosis in patients with certain tumor types[146-149].

FINDING SUMMARY

MSH6 encodes MutS homolog 6 protein, a member of the mismatch repair (MMR) gene family. Defective MMR occurring as a result of mutation(s) in the MMR family (MLH1, MSH2, MSH6, or PMS2) can result in microsatellite instability (MSI), common in colon, endometrium, and stomach cancers[135]. Alterations such as seen here may disrupt MSH6 function or expression[150-155].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in MSH6 are associated with both "typical" and "atypical" forms of autosomal dominant Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer or HNPCC), which accounts for 1-7% of all colorectal cancers[156]. Approximately 10% of all Lynch syndrome-associated mutations have been attributed to alterations in MSH6[157]. Carriers of mutations in MSH6 have a 60-80% risk of colorectal cancer[158]. Lynch syndrome has an estimated prevalence in the general population ranging from 1:600 to 1:2000[156,159-160]. Biallelic germline mutation of MSH6 has been shown to account for 20% of cases of the very rare syndrome Constitutional Mismatch Repair Deficiency (CMMRD), which is characterized by a 95% incidence rate of childhood onset lymphoma, leukemia and brain tumors, followed by early-onset colorectal cancer[161-165]. Given the association between MSH6 and these inherited syndromes, in the appropriate clinical context, germline testing of MSH6 is recommended.

GENE
NFE2L2

ALTERATION
D77H

TRANSCRIPT ID
NM_006164

CODING SEQUENCE EFFECT
229G>C

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

A study of patients with localized non-small cell lung cancer (NSCLC) identified pathogenic KEAP1 and NFE2L2 mutations as predictors of local recurrence following radiotherapy but not surgery; limited preclinical data also showed that treatment with a glutaminase inhibitor sensitized KEAP1-mutated NSCLC cells to radiation[166]. In other preclinical studies, treatment with AKT inhibitors sensitized lung cancer cells harboring KEAP1 or NFE2L2 mutations to both chemotherapy and radiation therapy[167-168]. There are no approved therapies that directly target NFE2L2 alterations; however, activating alterations in NFE2L2 may indicate sensitivity to mTORC1/2 inhibitors[169-170]. A Phase 2 study of the mTORC1/2 inhibitor sapanisertib for patients with advanced or recurrent lung squamous cell carcinoma (SCC) reported a 29% (2/7) ORR and a 100% (7/7) DCR for patients with NFE2L2 alterations[171].

FREQUENCY & PROGNOSIS

NFE2L2 alterations have been reported in several cancer types, including tumors affecting the head and neck (13-25%), lung (4-11%), esophagus (11%), or skin (6%)[60,172-173]. In the context of lung cancer, NFE2L2 mutations are most prevalent in smokers and patients with squamous cell carcinomas (SCC); NFE2L2 mutations also correlate with poor survival in multivariate analysis (mean survival 55 months vs. 81 months)[173-174]. NRF2 protein expression correlates with poor patient prognosis in lung cancer[175], colorectal cancer[176], gastric cancer[177-178], esophageal SCC[179], and osteosarcoma[180], among others. Additionally, cancers with increased NRF2 activity show increased resistance to chemotherapy and radiotherapy[177-179,181].

FINDING SUMMARY

NFE2L2 encodes nuclear factor E2-related factor 2 (NRF2), a transcription factor that plays a critical role in responses to oxidative and electrophilic stress[182]. NRF2 activity is antagonized by KEAP1, which binds NRF2 to promote its ubiquitination and subsequent degradation[183]. NRF2 missense mutations tend to cluster within the KEAP1 binding domain (especially amino acids 21-36 and 74-86); these mutations prevent degradation and lead to high levels of NRF2 protein and constitutive expression of NRF2 target genes[173]. These mutations are considered activating.

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
RBM10

ALTERATION
A184fs*80

TRANSCRIPT ID
NM_005676

CODING SEQUENCE EFFECT
551_557delCTACACG

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies approved or clinical trials that directly address genomic alterations in RBM10.

FREQUENCY & PROGNOSIS

Recurrent somatic mutations in RBM10 have been identified in breast, colorectal, ovarian, pancreatic, lung, and prostate cancers and in <1.0% of hematopoietic and lymphoid samples analyzed in COSMIC (Jul 2021)[59,117,184-186]. In breast cancer, RBM10 expression, as well as the other RBM genes on the X chromosome, RBMX and RBM3, has been shown to be correlated with expression of both caspase-3 and the pro-apoptotic gene BAX, leading the authors to hypothesize that RBM10 may play a role in apoptosis in breast cancer[187-188].

FINDING SUMMARY

RBM10 encodes RNA binding motif protein 10, a nuclear RNA-binding protein involved in the regulation of alternative splicing[189-190]. Germline mutations in RBM10 cause TARP syndrome, an X-linked recessive disorder characterized by development of micrognathia, glossoptosis, and cleft palate[191-192].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE

TP53

ALTERATION
R158fs*12

TRANSCRIPT ID
NM_000546

CODING SEQUENCE EFFECT
472_473CG>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[193-196], or p53 gene therapy and immunotherapeutics such as SGT-53[197-201] and ALT-801[202]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[203]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[204]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[205]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[206]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel[207]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[208]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[209]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[201]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[210-211]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[212-213]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

TP53 is one of the most commonly mutated genes in lung cancer; mutations have been reported in 43-80% of non-small cell lung cancers (NSCLCs)[60-61,214-219], including 42-52% of lung adenocarcinomas and 58-83% of lung squamous cell carcinomas (cBioPortal, COSMIC, Feb 2021)[59-61,220]. TP53 homozygous deletion has been observed in 1.4% of lung adenocarcinoma and <1% of lung squamous cell carcinoma cases (cBioPortal, Feb 2021)[115-116]. In one study of 55 patients with lung adenocarcinoma, TP53 alterations correlated with immunogenic features including PD-L1 expression, tumor mutation burden and neoantigen presentation; likely as a consequence of this association TP53 mutations correlated with improved clinical outcomes to PD-1 inhibitors pembrolizumab and nivolumab in this study[221]. Mutations in TP53 have been associated with lymph node metastasis in patients with lung adenocarcinoma[222].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[223]. Alterations such as seen here may disrupt TP53 function or expression[224-228].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[229-231], including sarcomas[232-233]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[234] to 1:20,000[233]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[235]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[88-93]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[88-89]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[94]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[92,95-96]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Afatinib

Assay findings association

EGFR
L858R

AREAS OF THERAPEUTIC USE

Afatinib is an irreversible kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4. It is FDA approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) and nonresistant EGFR mutations and for the treatment of patients with metastatic, squamous NSCLC after progression on platinum-based chemotherapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non-small cell lung cancer[40-41,236-237] , whereas data for patients with other tumor types are limited[43-48,238] .

SUPPORTING DATA

Afatinib has shown significant clinical activity for patients with NSCLC and the EGFR common sensitizing mutations L858R or exon 19 deletions, based on extensive clinical evidence[40,236,239-242] . Two randomized Phase 3 trials reported significantly improved median PFS from afatinib compared with chemotherapy for patients with EGFR common sensitizing mutations (LUX-Lung 3, 13.6 vs. 6.9 months, HR 0.47, p<0.001; LUX-Lung 6, 11.0 vs. 5.6 months, HR 0.28, p<0.0001)[40,236] . However, while afatinib significantly increased OS relative to chemotherapy for patients with EGFR exon 19 alterations in these two trials (LUX-Lung 3, 33.3 vs. 21.1 months, HR=0.54; LUX-Lung 6, 31.4 vs. 18.4 months, HR=0.64), no significant OS differences were observed in treatment for patients with L858R mutation[78]. A similar alteration-specific difference was observed for EGFR-mutated treatment-naive NSCLC in a retrospective analysis, which reported numerically longer median OS from second- versus first-generation EGFR TKIs (48.8 vs. 26.4 months, HR=0.59) for patients with exon 19 deletions, but no substantial difference for patients with L858R (25.4 vs. 20.6 months, HR=0.90)[239]. A Phase 2b study of first-line afatinib compared with gefitinib, also for NSCLC with exon 19 deletions or L858R, reported similar median OS for the two therapies (27.9 vs. 24.5 months, HR=0.86) but significantly longer time-to-treatment-failure (13.7 vs. 11.5 months, HR=0.75) and higher ORR (73% vs. 56%, p=0.0018) with afatinib[240]. Patients with metastatic NSCLC and common EGFR mutations who progressed on prior chemotherapy experienced an ORR of 50.0% (30/60) from afatinib in a Phase 4 trial[241]. As first-line therapy for NSCLC with EGFR exon 19 deletions or L858R, prospective or randomized Phase 2 trials have reported a median PFS of 10.2 months and OS of 24.8 months for patients unfit for chemotherapy[242] and an ORR of 72.5% (n=40, 1 CR), DCR of 100% (40/40), and median PFS and OS of 15.2 and 30.0 months, respectively, for elderly patients ≥70 years old[243]. A retrospective study of afatinib administered to Asian patients with NSCLC, 99% of whom were previously treated with erlotinib and/or gefitinib, reported an ORR of 27.4% (63/230) for patients with common sensitizing EGFR mutations and an ORR of 24.4% (105/431) for the entire cohort[244]. In a case report, a patient with NSCLC with exon 19 deletion and leptomeningeal metastases experienced an ongoing 16-month PR from afatinib in extracranial, brain, and leptomeningeal lesions[245]. For patients with erlotinib- or gefitinib-resistant NSCLC and EGFR mutations, Phase 2/3 studies of afatinib treatment have generally reported ORRs of only 7 to 9%[246-251] ; however, DCRs of more than 50% have been observed[250]. In a Phase 1b or observational study, patients with EGFR-mutated NSCLC who progressed on afatinib experienced further clinical benefit from subsequent treatment with afatinib and cetuximab[252] or osimertinib[253], respectively. Extensive clinical data have demonstrated that afatinib is effective for patients with EGFR-mutated advanced NSCLC, including exon 19 deletions and L858 mutations, as well as uncommon sensitizing mutations in exons 18 or 20[40,78,236,240,242,244,254] . Afatinib has also shown activity for patients with advanced NSCLC and ERBB2 mutations, most of which were exon 20 insertions[250,255-265] . The randomized Phase 3 LUX-Lung 8 trial comparing afatinib with erlotinib as second-line therapy for advanced lung squamous cell carcinoma (SCC) reported significantly longer median OS (7.9 vs. 6.8 months, HR=0.81), significantly longer median PFS (2.6 vs. 1.9 months, HR=0.81), and higher DCR (51% vs. 40%, p=0.002) for patients treated with afatinib[254]. For patients who progressed on afatinib monotherapy, additional clinical benefit has been reported from afatinib combined with paclitaxel[266].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Atezolizumab

Assay findings association

Blood Tumor Mutational Burden
38 Muts/Mb

AREAS OF THERAPEUTIC USE

Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC) and urothelial carcinoma, depending on treatment setting. Atezolizumab is also approved in combination with other therapies to treat patients with non-squamous NSCLC lacking EGFR or ALK alterations, small cell lung cancer, hepatocellular carcinoma, and BRAF V600-positive melanoma. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical data[1-3,267] , patients with NSCLC whose tumors harbor a bTMB of 10 Muts/Mb or higher may experience greater benefit from treatment with immune checkpoint inhibitors targeting PD-1 or PD-L1.

SUPPORTING DATA

The Phase 2 B-F1RST study prospectively evaluated blood tumor mutational burden (bTMB) as a biomarker of response to first-line atezolizumab in non-small cell lung cancer (NSCLC), reporting improved ORR (29% vs. 4.4%) and a trend toward improved median PFS (mPFS; 5.0 vs. 3.5 months, HR=0.80) and median OS (mOS; 23.9 vs. 13.4 months, HR=0.66) for patients with bTMB ≥16 Muts/Mb compared with bTMB <16 Muts/Mb; improved PFS and OS were seen with increasing bTMB cutoffs[268]. Retrospective analysis of the Phase 3 IMpower110 study of first-line atezolizumab for patients with metastatic NSCLC reported improved mOS (11.2 vs. 10.3 months, HR=0.87) and mPFS (5.5 vs. 4.3 months, HR=0.74) compared with chemotherapy for patients with bTMB levels ≥10 Muts/Mb (approximate equivalency ≥9 Muts/Mb as measured by this assay), with greater efficacy observed at higher bTMB cutoffs[269]. Retrospective analysis of the Phase 3 OAK and Phase 2 POPLAR trials for patients with advanced or metastatic NSCLC reported atezolizumab significantly improved OS across bTMB levels compared with docetaxel (p=0.0001); patients with bTMB levels ≥10 Muts/Mb (approximate equivalency ≥9 Muts/Mb as measured by this assay) achieved greater clinical benefit with atezolizumab than those with bTMB <10 Muts/Mb, with greater efficacy observed at higher bTMB cutoffs[1,270] ; patients with two or more mutations in DNA damage response and repair pathway genes (DDR) had an increased bTMB (20 vs. 7 muts/Mb), and reported a superior durable clinical benefit compared with patients without DDR mutations (57% vs. 31%, p=0.003)[271]. In the first-line setting, the Phase 3 IMpower130, IMpower150, and IMpower132 studies have shown that the addition of atezolizumab to chemotherapy-based regimens significantly improves survival for patients with non-squamous NSCLC without EGFR or ALK alterations[57,272-273] . In IMpower130, median PFS (7.0 vs. 5.5 months, HR=0.64) and median OS (18.6 vs. 13.9 months, HR=0.79) were significantly improved with atezolizumab plus nab-paclitaxel and carboplatin relative to chemotherapy alone; benefit was observed irrespective of PD-L1 status[272]. Similarly, IMpower150 reported improved median PFS (8.3 vs. 6.8 months, HR=0.62) and median OS (19.2 vs. 14.7 months, HR=0.78) with the addition of atezolizumab to bevacizumab, paclitaxel, and carboplatin; longer PFS was observed irrespective of PD-L1 status or KRAS mutation[57]. In IMpower132, the addition of atezolizumab to first-line carboplatin or cisplatin with pemetrexed in non-squamous NSCLC increased median PFS (7.6 vs. 5.2 months, HR=0.60) relative to chemotherapy alone[273]. The Phase 3 IMpower110 study of first-line atezolizumab for patients with metastatic non-small cell lung cancer (NSCLC) reported improved median OS (mOS; 20.2 vs. 13.1 months, HR=0.59), median PFS (8.1 vs. 5.0 months), and ORR (38% vs. 29%) compared with chemotherapy for patients whose tumors had high PD-L1 expression and no genomic alterations in EGFR or ALK[269]. The Phase 3 OAK trial comparing atezolizumab with docetaxel for patients with previously treated NSCLC reported a significant increase in mOS (13.8 vs. 9.6 months) and duration of response (16.3 vs. 6.2 months)[274], confirming previous Phase 2 trial data[275-276] . In the OAK trial, improved OS was observed for patients, regardless of histology (HR=0.73 for squamous and non-squamous) or PD-L1 status, although greater benefit was reported for patients with high PD-L1 tumor cell (>50%) or tumor-infiltrating immune cell (>10%) expression (HR=0.41) compared with those possessing <1% expression on either cell type (HR=0.75)[274]. Retrospective analyses of the OAK trial also identified clinical benefit for patients receiving atezolizumab and metformin compared with atezolizumab alone (ORR of 25% vs. 13%)[277], and for patients with 2 or more mutations in DNA damage response and repair pathway genes compared with those without (durable clinical benefit rate of 57% vs. 31%, p=0.003)[271]. The Phase 3 IMpower010 study of adjuvant atezolizumab treatment following adjuvant chemotherapy for patients with resected Stage II-IIIA NSCLC reported improved median disease-free survival compared with best supportive care (42.3 vs. 35.3 months, HR=0.79), with the greatest benefit observed for patients with PD-L1 tumor cell expression of ≥1% (not reached vs. 35.3 months, HR=0.66)[278]. In the randomized Phase 2 CITYSCAPE study of treatment-naive advanced NSCLC, the addition of tiragolumab to atezolizumab showed clinically meaningful improvement in ORR (37% [25/67] vs. 21% [14/68]) and PFS (5.6 vs. 3.9 months, HR=0.58), with greater ORR (66% [19/29] vs. 24% [7/29]) and PFS (not reached vs. 4.1 months, HR=0.30) observed for patients with PD-L1 tumor proportion scores (TPS) ≥50%[279].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Cemiplimab

Assay findings association

Blood Tumor Mutational Burden
38 Muts/Mb

AREAS OF THERAPEUTIC USE

Cemiplimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved to treat patients with NSCLC with high PD-L1 expression (TPS ≥ 50%), cutaneous squamous cell carcinoma (CSCC), or basal cell carcinoma (BCC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical data[1-3,267] , patients with NSCLC whose tumors harbor a bTMB of 10 Muts/Mb or higher may experience greater benefit from treatment with immune checkpoint inhibitors targeting PD-1 or PD-L1.

SUPPORTING DATA

The Phase 3 EMPOWER-Lung 1 trial for treatment-naive advanced non-small cell lung cancer (NSCLC) reported that cemiplimab improved median PFS (mPFS, 8.2 vs. 5.7 months, hazard ratio [HR]=0.54), median OS (mOS, not reached vs. 14.2 months, HR=0.57), and ORR (39% vs. 20%) compared with chemotherapy in patients with high PD-L1 expression (TPS ≥ 50%); improved mPFS (6.2 vs. 5.6 months, HR=0.59), mOS (22.1 vs. 14.3 months, HR=0.68), and ORR (37% vs. 21%) were also reported for cemiplimab over chemotherapy in the intention-to-treat population[280]. In a Phase 2 trial of cemiplimab-containing regimens as second-line therapy for NSCLC, cemiplimab combined with ipilimumab elicited a numerically higher ORR (46% [5/11]) compared with high-dose (11% [1/9]) and standard-dose cemiplimab monotherapy (0% [0/8])[281].

Dacomitinib

Assay findings association

EGFR
L858R

AREAS OF THERAPEUTIC USE

Dacomitinib is a second generation irreversible tyrosine kinase inhibitor that targets the kinase domains of EGFR, ERBB2/HER2, and ERBB4/HER4. It is FDA approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR activating mutations may indicate sensitivity to afatinib or dacomitinib for patients with non-small cell lung cancer[40-41,236-237] , whereas data for patients with other tumor types are limited[43-48,238] . Patients with untreated advanced NSCLC and EGFR L858R mutations achieved an ORR of 73% (68/93)[282] and a median OS of 32.5 months with dacomitinib[41].

SUPPORTING DATA

A randomized Phase 3 trial in patients with NSCLC with activating EGFR mutations (primarily L858R or exon 19 deletions) reported improved clinical benefit with first-line dacomitinib compared with gefitinib (median OS, 34.1 vs. 26.8 months, HR=0.760; median PFS, 14.7 vs. 9.2 months, HR=0.59)[282-283] ; median OS was 34.1 to 36.7 months and ORR was 74.9% to 79.3%, depending on the dosing regimen[284]. A pooled subgroup analysis of patients with NSCLC with activating EGFR mutations reported improved clinical efficacy with dacomitinib treatment compared with erlotinib (median PFS, 14.6 vs, 9.6 months, HR=0.717; median OS, 26.6 vs, 23.2 months, HR=0.737)[285]. Reduced efficacy of dacomitinib treatment in patients with NSCLC harboring the EGFR T790M mutation has been reported in multiple studies[286-288] . A Phase 1 trial of combination dacomitinib and a MEK1/2 inhibitor for patients with KRAS-mutated CRC, NSCLC, or pancreatic cancer reported 20/36 SDs and 16 PDs, however toxicity from this combination prevented long-term treatment in this patient population[289]. A Phase 2 study of dacomitinib in patients with NSCLC who had been previously treated with chemotherapy or erlotinib and were not selected for EGFR mutations reported an ORR of 4.5% (3/66)[287]. In one study, the combination of dacomitinib and crizotinib was ineffective and associated with high toxicity in patients with NSCLC[290].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Dostarlimab

Assay findings association

Blood Tumor Mutational Burden
38 Muts/Mb

AREAS OF THERAPEUTIC USE

Dostarlimab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor response. It is FDA approved to treat patients with mismatch repair deficient recurrent or advanced endometrial cancer or solid tumors. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical data[1-3,267] , patients with NSCLC whose tumors harbor a bTMB of 10 Muts/Mb or higher may experience greater benefit from treatment with immune checkpoint inhibitors targeting PD-1 or PD-L1.

SUPPORTING DATA

In the Phase 1 GARNET trial of dostarlimab, patients with non-small cell lung cancer (NSCLC) experienced an immune-related ORR (irORR) of 27% with 2 CRs[291]. Dostarlimab has been studied primarily in recurrent and advanced mismatch repair-deficient (dMMR) endometrial and non-endometrial cancers[292-294] . In the Phase 1 GARNET trial, single-agent dostarlimab elicited an ORR of 39% (41/106) and an immune-related ORR of 46% (50/110) for patients with non-endometrial dMMR solid tumors[292,295] .

Durvalumab

Assay findings association

Blood Tumor Mutational Burden
38 Muts/Mb

AREAS OF THERAPEUTIC USE

Durvalumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 to enhance antitumor immune responses. It is FDA approved to treat patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical data[1-3,267] , patients with NSCLC whose tumors harbor a bTMB of 10 Muts/Mb or higher may experience greater benefit from treatment with immune checkpoint inhibitors targeting PD-1 or PD-L1.

SUPPORTING DATA

The MYSTIC trial for patients with treatment-naïve, EGFR/ALK-negative metastatic NSCLC reported that a bTMB score ≥20 Muts/Mb (approximately 10 Muts/Mb as measured by this assay) associated with improved survival following either a combination treatment of durvalumab with the CTLA-4 inhibitor tremelimumab, regardless of tumor PD-L1 expression, or following durvalumab monotherapy for patients with tumor cell PD-L1 expression <1%[267]. In the Phase 3 PACIFIC trial for patients with Stage 3 unresectable non-small cell lung cancer (NSCLC) who did not have progression on chemoradiotherapy, durvalumab monotherapy improved PFS versus placebo across PD-L1 expression subgroups; median PFS (mPFS) was 23.9 versus 5.6 months (HR=0.49) for patients with PD-L1 expression ≥1% and 10.7 versus 5.6 months (HR=0.79) for patients with PD-L1 expression <1%. Median OS (mOS) benefit was observed for patients with PD-L1 expression ≥1% (57.4 vs. 29.6 months, HR=0.60), but not for those with PD-L1 expression <1% (33.9 vs. 43.0 months, HR=1.05)[296-297] . In the Phase 3 ARCTIC study for patients with metastatic NSCLC who had progressed on 2 or fewer prior therapies, single-agent durvalumab improved OS (11.7 vs. 6.8 months, HR=0.63) and PFS (3.8 vs. 2.2 months, HR=0.71) versus the investigator's choice of standard of care (SOC) for patients in cohort A (PD-L1 ≥25%)[298]. However, durvalumab plus tremelimumab did not significantly improve OS (11.5 vs. 8.7 months, HR=0.80) or PFS (3.5 vs. 3.5 months, HR=0.77) compared with SOC for patients in cohort B (PD-L1 <25%)[298]. In the Phase 3 MYSTIC trial for patients with treatment-naive EGFR- or ALK-negative metastatic NSCLC and PD-L1 expression ≥25%, neither durvalumab monotherapy nor durvalumab plus tremelimumab improved OS versus chemotherapy (HR=0.76 vs. HR=0.85); however, patients with blood tumor mutational burden (bTMB) ≥20 Muts/Mb showed improved OS for durvalumab plus tremelimumab versus chemotherapy (21.9 vs. 10.0 months, HR=0.49)[299]. In the Phase 3 POSEIDON trial for patients with treatment-naive EGFR- or ALK-negative metastatic NSCLC, the addition of durvalumab and tremelimumab to chemotherapy improved mOS (14.0 vs. 11.7 months, HR=0.77) and mPFS (6.2 vs 4.8 months, HR=0.72) versus chemotherapy[300]. In Phase 2 trials for patients with advanced or relapsed NSCLC, improved ORR[301-302] and OS[301] for durvalumab monotherapy corresponded with increased tumor cell PD-L1 positivity; patients with very high PD-L1 expression (≥90%) had an ORR of 31% (21/68) compared with ORRs of 16% (24/146) for patients with ≥25% and 7.5% (7/93) for patients with <25% PD-L1 positivity[302]. Re-treatment with durvalumab for patients with PD-L1-positive (≥25%) EGFR-negative or ALK-negative advanced NSCLC who had progressed following previous disease control resulted in a PR or SD for 25% (10/40) of patients[303].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Erlotinib

Assay findings association

EGFR
L858R

AREAS OF THERAPEUTIC USE

Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression[38,304-306] .

SUPPORTING DATA

For patients with EGFR-mutated NSCLC, the Phase 3 EURTAC trial reported improved PFS with first-line erlotinib relative to platinum-based chemotherapy (9.7 vs. 5.2 months, HR=0.37)[38]. A Phase 3 study reported similar efficacy of erlotinib and gefitinib for patients with EGFR-mutated NSCLC[307]. Meta-analysis of studies comparing erlotinib or gefitinib versus chemotherapy in the first-line setting reported no significant improvement in OS for patients with EGFR-mutated NSCLC; however, the lack of improved OS was attributed to the effectiveness of postprogression salvage therapy[308]. In the maintenance setting, the placebo-controlled Phase 3 SATURN trial reported significantly improved PFS with maintenance erlotinib following first-line platinum-based chemotherapy irrespective of EGFR status; however, the largest effect was seen for patients with EGFR mutations (HR=0.10)[304]. In the neoadjuvant setting, a Phase 2 trial reported a numerically improved ORR and significantly longer PFS with erlotinib compared with chemotherapy for patients with advanced EGFR-mutated NSCLC[305]. In the placebo-controlled Phase 3 RELAY trial, the addition of ramucirumab to erlotinib improved PFS for previously untreated patients with NSCLC harboring EGFR L858R or exon 19 deletion (19.4 vs. 12.4 months, HR=0.59)[309]. In a Phase 2 trial, no clinical benefit was observed from the addition of bevacizumab to erlotinib for patients with NSCLC harboring EGFR exon 19 deletion or L858R mutation[310]. The Phase 3 BR.21 trial demonstrated prolonged OS for genomically unselected patients with NSCLC treated with erlotinib compared with those treated with standard chemotherapy[311].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Gefitinib

Assay findings association

EGFR
L858R

AREAS OF THERAPEUTIC USE

Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy[306,312-317] , and responses have been reported for patients with EGFR-rearranged NSCLC[318-319] .

SUPPORTING DATA

A Phase 3 trial of first-line gefitinib therapy for patients with NSCLC and EGFR exon 19 deletions or L858R mutations reported a longer PFS (9.2 months vs. 6.3 months)[314] but no change in median OS (34.9 months vs. 37.2 months) compared with patients treated with cisplatin plus docetaxel (median OS of 37.2 months)[320]. Gefitinib achieved an ORR of 69.8% and an OS of 19.2 months as first-line treatment for Caucasian patients with non-small cell lung carcinoma (NSCLC) and EGFR sensitizing mutations[39]. In the retrospective analysis of a Phase 3 study for East Asian patients, gefitinib was reported to have a longer PFS for patients with EGFR mutation-positive NSCLC compared with carboplatin/paclitaxel doublet chemotherapy[315,321] . Two Phase 3 trials of gefitinib plus pemetrexed and carboplatin compared with gefitinib alone for patients with advanced NSCLC harboring EGFR activating mutations reported significantly higher ORRs (75.3% and 84% vs. 62.5% and 67%), longer median PFSs (16 and 20.9 months vs. 8 and 11.9 months), and longer median OSs (50.9 months and not reached vs. 17 and 38.8 months) with combination treatment; however, combination treatment was associated with increased Grade 3 or higher adverse events[322-323] . Retrospective analysis of East Asian patients with advanced NSCLC receiving first-line gefitinib therapy reported that patients with EGFR exon 19 mutations experienced a longer median PFS (10.9 months) compared with patients with EGFR mutations in exon 18 (7.9 months), exon 20 (1.2 months), exon 21 (7.7 months), or double mutations (5.7 months); however, no differences in OS were seen between EGFR mutations[324]. In a Phase 1 study for treatment-naive patients with NSCLC, best ORRs of 78% (7/9) were observed in patients treated with combination gefitinib and the PD-L1 inhibitor durvalumab as first-line treatment and of 80% (8/10) in those treated with the combination after gefitinib monotherapy[325].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Nivolumab

Assay findings association

Blood Tumor Mutational Burden
38 Muts/Mb

AREAS OF THERAPEUTIC USE

Nivolumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, reducing inhibition of the antitumor immune response. It is FDA approved as monotherapy in various treatment settings for patients with melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, classical Hodgkin lymphoma (cHL), gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma or squamous cell carcinoma (ESCC). Furthermore, nivolumab is approved to treat patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC). It is also approved in combination with cabozantinib to treat RCC. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical data[1-3,267] , patients with NSCLC whose tumors harbor a bTMB of 10 Muts/Mb or higher may experience greater benefit from treatment with immune checkpoint inhibitors targeting PD-1 or PD-L1.

SUPPORTING DATA

For patients with platinum-refractory non-squamous non-small cell lung cancer (NSCLC), nivolumab improved median OS (mOS; 12.2 vs. 9.4 months) and ORR (19% vs. 12%) compared with docetaxel in the Phase 3 CheckMate 057 study; PD-L1 expression was associated with OS benefit from nivolumab in this study (HR=0.40-0.59)[326]. In advanced squamous NSCLC, second-line nivolumab resulted in longer mOS (9.2 vs. 6.0 months) and higher ORR (20% vs. 9%) than docetaxel in the Phase 3 CheckMate 017 study; PD-L1 expression was neither prognostic nor predictive of nivolumab efficacy[327-328] . Pooled analysis of CheckMate 057 and CheckMate 017 showed improved long-term OS and PFS benefit for nivolumab over docetaxel, with 5-year OS rates of 13% versus 2.6% (HR=0.68) and PFS rates of 8.0% versus 0% (HR=0.79)[329]. In the CheckMate 227 study, the combination of nivolumab and platinum-based doublet chemotherapy did not improve OS over chemotherapy alone (18.3 vs. 14.7 months, HR=0.81)[330], despite Phase 1 results in the same setting suggesting improved ORR and OS[331]. In the Phase 3 CheckMate 816 study, the combination of nivolumab and platinum-based doublet chemotherapy did show benefit as a neoadjuvant treatment for patients with resectable NSCLC, reporting a pathological CR (pCR) rate of 24% versus 2.2% for chemotherapy alone, and the benefit was consistent across subgroups stratified by PD-L1 expression, stage of disease, or tumor mutational burden (TMB)[332]. A Phase 1 study of nivolumab combined with the immunostimulatory therapy bempegaldesleukin for immunotherapy-naive patients with NSCLC reported an ORR of 60% (3/5; 2 CRs) and mPFS of 18.0 months[333].

Osimertinib

Assay findings association

EGFR
L858R

AREAS OF THERAPEUTIC USE

Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI-sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR TKI-sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non-small cell lung cancer[42,318,334-336] . Patients with untreated advanced NSCLC and EGFR exon 19 deletions or L858R mutations achieved an ORR of 80% and a median PFS of 21.4 and 14.4 months, respectively[334].

SUPPORTING DATA

The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first-line osimertinib significantly increased both median PFS (18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced NSCLC and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858)[334,337] . In the Phase 3 ADAURA study, patients with early Stage (IB/II/IIIA) EGFR-mutated NSCLC experienced longer PFSs on osimertinib compared to placebo in the adjuvant setting (not reached vs. 28.1 months; HR=0.21)[338]. A Phase 1 study reported that T790M-negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months[42]. A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR-mutated, T790M-negative NSCLC reported an ORR of 19% (4/19), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non-small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213)[339]. The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR-sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47)[340]. The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR-mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively[341].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Pembrolizumab

Assay findings association

Blood Tumor Mutational Burden
38 Muts/Mb

AREAS OF THERAPEUTIC USE

Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2 to enhance antitumor immune responses. It is FDA approved for patients with tumor mutational burden (TMB)-high (≥10 Muts/Mb), microsatellite instability-high (MSI-H), or mismatch repair-deficient (dMMR) solid tumors; as monotherapy for PD-L1-positive non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), cervical cancer, or gastric, esophageal, or gastroesophageal junction (GEJ) cancer; and in combination with chemotherapy for PD-L1-positive triple-negative breast cancer (TNBC) or cervical cancer. It is also approved in various treatment settings as monotherapy for patients with melanoma, HNSCC, urothelial carcinoma, hepatocellular carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma, classical Hodgkin lymphoma, or primary mediastinal large B-cell lymphoma, and in combination with chemotherapy or targeted therapy for NSCLC, HNSCC, esophageal or GEJ cancer, renal cell carcinoma, TNBC, or endometrial carcinoma that is not MSI-H or dMMR. Please see the drug label for full prescribing information. A voluntary withdrawal of the accelerated approval of pembrolizumab for the treatment of patients with recurrent advanced PD-L1-positive gastric or GEJ adenocarcinoma with disease progression on or after two or more prior lines of therapy has been initiated by the manufacturer.

GENE ASSOCIATION

On the basis of clinical data[1-3,267] , patients with NSCLC whose tumors harbor a bTMB of 10 Muts/Mb or higher may experience greater benefit from treatment with immune checkpoint inhibitors targeting PD-1 or PD-L1.

SUPPORTING DATA

A pilot study for first-line pembrolizumab alone or in combination with chemotherapy, for patients with newly diagnosed metastatic NSCLC, reported significantly improved median PFS in patients with bTMB levels ≥16 Muts/Mb (approximately 8 Muts/Mb as measured by this assay) compared with those with bTMB <16 Muts/Mb (14.1 vs. 4.7 months, HR=0.30); median OS was not reached in the bTMB ≥16 Muts/Mb cohort, compared with 8.8 months for those with bTMB <16 (HR=0.48)[3]. The superiority of pembrolizumab over platinum chemotherapy as first-line treatment for patients with PD-L1-positive non-small cell lung cancer (NSCLC) lacking EGFR or ALK alterations was demonstrated in the Phase 3 KEYNOTE-042 and -024 studies, which reported improved median OS (mOS) for PD-L1 tumor proportion scores (TPS) ≥1% (16.7 vs. 12.1 months, HR=0.81)[342] and ≥50% (26.3 vs. 13.4 months, HR=0.62-0.69)[343], with estimated 5-year OS rates of 32% versus 16% in the KEYNOTE-024 study[343]. In the Phase 1b KEYNOTE-100 study of pembrolizumab, mOS was numerically higher for patients with NSCLC and PD-L1 TPS ≥50% relative to those with lower levels of PD-L1 expression in both the first-line (35.4 vs. 19.5 months) and previously treated (15.4 vs. 8.5 months) settings[344]. A retrospective study showed that among patients with NSCLC and high PD-L1 expression treated with first-line pembrolizumab, mOS was improved for patients with TPS of 90-100% relative to those with TPS of 50-89% (not reached vs. 15.9 months, HR=0.39)[345]. Phase 3 studies showed that the addition of pembrolizumab to chemotherapy is superior to chemotherapy alone in the first-line setting for patients with either non-squamous (KEYNOTE-189)[346] or squamous (KEYNOTE-407)[347-348] NSCLC, regardless of PD-L1 or tumor mutational burden (TMB) status[349]. An exploratory analysis of KEYNOTE-189 demonstrated the superiority of the pembrolizumab combination therapy, regardless of blood TMB (bTMB) status[350]. For the first-line treatment of patients with NSCLC and high PD-L1 expression (TPS ≥50%), a meta-analysis of KEYNOTE-024 and -189 reported the combination of pembrolizumab and chemotherapy to be non-superior to pembrolizumab alone in terms of survival benefit; however, the combination did increase ORR (+22%, p=0.011)[351]. In the Phase 2/3 KEYNOTE-010 study, pembrolizumab extended mOS relative to docetaxel (10.4-12.7 vs. 8.2 months) for patients with previously treated PD-L1-positive NSCLC[352]. Multiple clinical trials have demonstrated the efficacy of pembrolizumab, both as a single agent and in combination with chemotherapy, to treat patients with NSCLC and brain metastases[353-355] . Clinical activity has also been achieved with pembrolizumab in combination with the AXL inhibitor bemcentinib[356], the anti-CTLA-4 antibody ipilimumab[357], the anti-TIGIT antibody vibostolimab[358], the HDAC inhibitor vorinostat[359], the multikinase inhibitor lenvatinib[360], and the PARP inhibitor niraparib[361].

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Avelumab

Assay findings association

Blood Tumor Mutational Burden
38 Muts/Mb

AREAS OF THERAPEUTIC USE

Avelumab is a monoclonal antibody that binds to PD-L1 and blocks its interaction with PD-1 in order to enhance antitumor immune responses. It is FDA approved to treat patients 12 years and older with Merkel cell carcinoma, or for urothelial carcinoma in various treatment settings. The combination of avelumab and axitinib is FDA approved for patients with renal cell carcinoma (RCC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical data[1-3,267] , patients with NSCLC whose tumors harbor a bTMB of 10 Muts/Mb or higher may experience greater benefit from treatment with immune checkpoint inhibitors targeting PD-1 or PD-L1.

SUPPORTING DATA

In the Phase 3 JAVELIN Lung 200 study for patients with advanced non-small cell lung cancer (NSCLC) previously treated with platinum therapy, avelumab did not improve median OS (mOS) when compared with docetaxel (11.4 vs. 10.6 months; HR=0.87) for patients with PD-L1 expression in ≥1% of tumor cells; a prespecified exploratory analysis at higher PD-L1 expression cutoffs showed improved mOS for PD-L1 ≥50% (13.6 vs. 9.2 months; HR=0.67) and ≥80% (17.1 vs. 9.3 months; HR=0.59)[362], and improved 2-year OS rates of 30% versus 21% (≥1% PD-L1), 36% versus 18% (≥50% PD-L1), and 40% versus 20% (≥80% PD-L1)[363]. A post-hoc analysis of this study suggested that a relatively high proportion of patients in the docetaxel arm received subsequent immune checkpoint inhibitor treatment, which may have confounded the outcomes of this study[364]. A Phase 1 study evaluating single-agent avelumab to treat patients with advanced NSCLC reported an ORR of 20%, median PFS (mPFS) of 4.0 months, and mOS of 14.1 months in the first-line setting[365]. A Phase 2 study of avelumab with axitinib to treat advanced NSCLC reported an ORR of 32% (13/41) and mPFS of 5.5 months; tumor reduction was observed for PD-L1-negative and -positive (≥1% PD-L1) samples[366]. A Phase 1b/2 study of avelumab combined with the anti-semaphorin 4D antibody pepinemab to treat advanced NSCLC reported an ORR of 24% (5/21) and DCR of 81% for immunotherapy-naive patients, and ORR of 6.9% (2/29) and DCR of 59% for patients who had disease progression on prior immunotherapy treatment[367]. A study of neoadjuvant avelumab plus chemotherapy to treat early-stage resectable NSCLC reported an ORR of 27% (4/15), which was not considered an enhancement over chemotherapy alone[368].

NOTE Genomic alterations detected may be associated with activity of certain US FDA or other specific country approved therapies; however, the therapies listed in this report may have varied evidence in the patient's tumor type. The listed therapies are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. The therapies listed in this report may not be complete and/or exhaustive. Furthermore, the listed therapies are limited to US FDA approved pharmaceutical drug products that are linked to a specific genomic alteration. There may also be US FDA approved pharmaceutical drug products that are not linked to a genomic alteration. Further there may also exist pharmaceutical drug products that are not approved by the US FDA or other national authorities. There may also be other treatment modalities available than pharmaceutical drug products.

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

BIOMARKER

Blood Tumor Mutational Burden

RESULT

38 Muts/Mb

RATIONALE

Increased tumor mutational burden may predict response to anti-PD-1 (alone or in combination with anti-CTLA-4) or anti-PD-L1 immune checkpoint inhibitors.

NCT04237649

PHASE NULL

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

TARGETS ADORA2A, CD73, PD-1

LOCATIONS: Taipei (Taiwan), Sunto Gun (Japan), Singapore (Singapore), Milano (Italy), Barcelona (Spain), California, Illinois, Missouri, Connecticut, Texas

NCT03425643

PHASE 3

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

TARGETS PD-1

LOCATIONS: Taipei (Taiwan), Kaohsiung (Taiwan), Ningbo (China), Hangzhou (China), Shanghai (China), Changsha (China), Kitakyushu (Japan), Yufu (Japan), Gyeonggi-do (Korea, Republic of), Hiroshima (Japan)

NCT03706690

PHASE 3

A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

TARGETS PD-L1

LOCATIONS: Taipei (Taiwan), Taipei City (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Fuzhou (China), Tainan (Taiwan), Wenzhou (China), Taizhou (China), Ningbo (China), Hangzhou (China)

NCT03800134

PHASE 3

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

TARGETS PD-L1

LOCATIONS: Taipei (Taiwan), Taipei City (Taiwan), Taoyuan (Taiwan), Taichung City (Taiwan), Changhua (Taiwan), Taichung (Taiwan), Tainan City (Taiwan), Xiamen (China), Linhai (China), Ningbo (China)

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT04026412

PHASE 3

A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery

TARGETS PD-1, PD-L1, CTLA-4

LOCATIONS: Taipei (Taiwan), New Taipei City (Taiwan), Fuzhou (China), Tainan (Taiwan), Kaohsiung (Taiwan), Linhai (China), Hangzhou (China), Nanchang (China), Nanjing (China), Changsha (China)

NCT04385368

PHASE 3

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

TARGETS PD-L1

LOCATIONS: Taipei (Taiwan), Taipei 112 (Taiwan), Taipei City (Taiwan), Tao-Yuan (Taiwan), Taichung (Taiwan), Chiayi (Taiwan), Hong Kong (Hong Kong), Hiroshima-shi (Japan), Cheongju-si (Korea, Republic of), Suwon-si (Korea, Republic of)

NCT04025879

PHASE 3

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

TARGETS PD-1

LOCATIONS: Taipei City (Taiwan), New Taipei City (Taiwan), Kaohsiung (Taiwan), Kaohsiung City (Taiwan), Hangzhou (China), Shanghai (China), Changsha (China), Kitakyushu-shi (Japan), Hiroshima (Japan), Kobe-shi (Japan)

NCT03674567

PHASE 1/2

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

TARGETS PD-1, CCR4

LOCATIONS: Taipei (Taiwan), Tainan (Taiwan), Shatin (Hong Kong), High West (Hong Kong), Ulsan (Korea, Republic of), Chungbuk (Korea, Republic of), Seoul (Korea, Republic of), Bangkok (Thailand), Nedlands (Australia), Heidelberg (Australia)

NCT02829723

PHASE 1/2

Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

TARGETS PD-1, CSF1R

LOCATIONS: Taipei (Taiwan), Tainan (Taiwan), Nagoya (Japan), Koto ku (Japan), Singapore (Singapore), Tel Aviv (Israel), Zurich (Switzerland), Rozzano (Italy), Barcelona (Spain), Hospitalet de LLobregat (Spain)

NCT03207867

PHASE 2

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

TARGETS PD-1, ADORA2A

LOCATIONS: Taipei (Taiwan), Koto ku (Japan), Singapore (Singapore), Brno (Czechia), Salzburg (Austria), Essen (Germany), Koeln (Germany), St. Gallen (Switzerland), Rotterdam (Netherlands), Liege (Belgium)

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
EGFR

ALTERATION
L858R

RATIONALE
EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.

NCT03521154

PHASE 3

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

TARGETS
EGFR

LOCATIONS: Taipei (Taiwan), Taoyuan (Taiwan), Taichung (Taiwan), Tainan City (Taiwan), Linhai (China), Hangzhou (China), Shanghai (China), Nanjing (China), Beijing (China), Guangzhou (China)

NCT04487080

PHASE 3

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

TARGETS
MET, EGFR

LOCATIONS: New Taipei (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Wenzhou (China), Linhai (China), Hangzhou (China), Hang Zhou (China), Shanghai (China), Busan (Korea, Republic of)

NCT04619004

PHASE 2

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

TARGETS
ERBB3

LOCATIONS: Taipei (Taiwan), Tainan City (Taiwan), Kaohsiung City (Taiwan), Fukuoka (Japan), Daegu (Korea, Republic of), Matsuyama (Japan), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Akashi (Japan), Ōsaka-sayama (Japan)

NCT02609776

PHASE 1

A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer

TARGETS
MET, EGFR

LOCATIONS: Taipei (Taiwan), Taipei City (Taiwan), Taichung (Taiwan), Hangzhou (China), Nanchang (China), Nanjing (China), Hefei (China), Guangzhou (China), Changsha (China), Wuhan (China)

NCT03114319

PHASE 1

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

TARGETS
SHP2, EGFR

LOCATIONS: Taipei (Taiwan), Seoul (Korea, Republic of), Kobe-shi (Japan), Singapore (Singapore), Amsterdam (Netherlands), Rotterdam (Netherlands), Barcelona (Spain), Hospitalet de LLobregat (Spain), Toronto (Canada), Massachusetts

NCT02099058

PHASE 1

A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors

TARGETS
MET, EGFR, PD-1

LOCATIONS: Taipei City (Taiwan), Taichung City (Taiwan), Tainan City (Taiwan), Seoul (Korea, Republic of), Chuo-ku (Japan), Kashiwa-shi (Japan), Marseille CEDEX 05 (France), California

NCT04077463

PHASE 1

A Study of Lazertinib as Monotherapy or in Combination With JNJ-61186372 in Japanese Participants With Advanced Non-small Cell Lung Cancer

TARGETS
EGFR, MET

LOCATIONS: Taipei City (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Hang Zhou (China), Shanghai (China), Guangzhou (China), Wuhan (China), Jinan (China), Seongnam-si (Korea, Republic of)

NCT04035486

PHASE 3

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

TARGETS
EGFR

LOCATIONS: Taichung (Taiwan), Shanghai (China), Nanchang (China), Nanjing (China), Yangzhou (China), Hefei (China), Guangzhou (China), Beijing (China), Urumqi (China), Zhengzhou (China)

NCT03720873

PHASE 2

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

TARGETS
EGFR, FGFRs, KIT, VEGFRs

LOCATIONS: Fuzhou (China)

NCT04058704

PHASE 3

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy

TARGETS
EGFR

LOCATIONS: Hangzhou (China)

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ATM
C198F

CARD11
V171M

CIC
G1027E and S313F

CREBBP
E982Q

CUL3
E386K

CYP17A1
R362C

DOT1L
rearrangement

ERBB3
I671_Q672>NE

FLT1
E726K

GNAS
D295Y and G370V

IKZF1
E387K

JAK3
L910F

KDM5A
H1637Y

MAP3K13
K876N

MLL2
E5006Q

MST1R
R306H

MYCL1
S189C

NF1
M2054N

NOTCH3
P995S

NTRK1
V99M

PARK2
E310V

PARP1
S499*

PIK3C2G
R704S

PIK3CA
K111_I112insKE

RB1
I422M

STAT3
H447N

ZNF703
K54N

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*C11orf30* (EMSY)	*C17orf39* (GID4)	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*
CCND1	*CCND2*	*CCND3*	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*
CD274 **(PD-L1)**	*CDC73*	***CDH1***	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*
CDKN2A	*CDKN2B*	*CDKN2C*	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***
CSF1R	*CSF3R*	*CTCF*	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*
DAXX	*DDR1*	***DDR2*** **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15**, 24-27**	*EP300*
EPHA3	*EPHB1*	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***
ESR1 **Exons 4-8**	*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FAM46C*	*FANCA*
FANCC	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*
FGF23	*FGF3*	*FGF4*	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*
FLCN	*FLT1*	***FLT3*** **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*
GNA11 **Exons 4, 5**	*GNA13*	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3F3A*	*HDAC1*	*HGF*
HNF1A	***HRAS*** **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*
INPP4B	*IRF2*	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*
KDM5C	*KDM6A*	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

KRAS	*LTK*	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*
MAPK1	*MCL1*	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***
MITF	*MKNK1*	*MLH1*	***MPL*** **Exon 10**	*MRE11A*	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*
MTAP	***MTOR*** **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*
NF1	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**
NRAS **Exons 2, 3**	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**
PDGFRB **Exons 12-21, 23**	*PDK1*	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TERC** ncRNA	***TERT**** **Promoter**	*TET2*
TGFBR2	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*	*TYRO3*
U2AF1	***VEGFA***	*VHL*	*WHSC1*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based *in vitro* diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. *Note:* A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For *in vitro* diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

to: *ASXL1*, *ATM*, *CBL*, *CHEK2*, *DNMT3A*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, *TP53*, and *U2AF1*.

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.2.0

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Nie W, et al. J Natl Compr Canc Netw (2020) pmid: 32380463
6. Ma Y, et al. Front Oncol (2021) pmid: 34055609
7. Xiao D, et al. Oncotarget (2016) pmid: 27009843
8. Chen Y, et al. J. Exp. Clin. Cancer Res. (2019) pmid: 31088500
9. Yu H, et al. J Thorac Oncol (2019) pmid: 30253973
10. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
11. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
12. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
13. Rizvi NA, et al. Science (2015) pmid: 25765070
14. Johnson BE, et al. Science (2014) pmid: 24336570
15. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
16. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
17. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
18. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
19. Nature (2012) pmid: 22810696
20. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
21. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
22. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
23. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
24. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
25. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
26. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
27. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
28. Lapin M, et al. J Transl Med (2018) pmid: 30400802
29. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
30. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
31. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
32. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
33. Fan G, et al. PLoS ONE (2017) pmid: 28187169
34. Vu et al., 2020; DOI: 10.1200/PO.19.00204
35. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
36. Zhang EW, et al. Cancer (2020) pmid: 32757294
37. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
38. Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168
39. Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064
40. Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960
41. Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379
42. Jänne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549
43. Hong MH, et al. Cancer (2020) pmid: 32749686
44. Kim HS, et al. Oncotarget (2015) pmid: 26462025
45. Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851
46. Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840
47. Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047
48. Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886
49. Leighl et al., 2021; ESMO Abstract 1192MO
50. Cho et al., 2020; ESMO Abstract 1258O
51. Bauml et al., 2021; ASCO Abstract 9006
52. Shu et al., 2021; ESMO Abstract 1193MO
53. Jänne PA, et al. Cancer Discov (2021) pmid: 34548309
54. Ahn MJ, et al. Lancet Respir Med (2017) pmid: 29056570
55. Yang Z, et al. Sci Transl Med (2016) pmid: 27928026
56. Ahn MJ, et al. Lancet Oncol (2019) pmid: 31587882
57. Socinski MA, et al. N. Engl. J. Med. (2018) pmid: 29863955
58. Vallee A, et al. Int. J. Oncol. (2013) pmid: 23934203
59. Imielinski M, et al. Cell (2012) pmid: 22980975
60. Nature (2014) pmid: 25079552
61. Nature (2012) pmid: 22960745
62. Watzka SB, et al. Eur J Cardiothorac Surg (2010) pmid: 20353893
63. Liang Z, et al. BMC Cancer (2010) pmid: 20637128
64. Grob TJ, et al. Lung Cancer (2013) pmid: 23238037
65. Park S, et al. Histol. Histopathol. (2012) pmid: 22207554
66. Dobashi Y, et al. Hum. Pathol. (2011) pmid: 21040950
67. Ludovini V, et al. Cancer Chemother. Pharmacol. (2013) pmid: 23314677
68. Skrzypski M, et al. Clin Lung Cancer (2013) pmid: 23870818
69. Kim SH, et al. Histol. Histopathol. (2012) pmid: 22419022
70. Lee JS, et al. Ann. Surg. Oncol. (2013) pmid: 23525704
71. Oakley GJ, et al. J Thorac Oncol (2011) pmid: 21587084
72. Marks JL, et al. J Thorac Oncol (2008) pmid: 18303429
73. Izar B, et al. Ann. Thorac. Surg. (2013) pmid: 23932319
74. Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605
75. Lynch TJ, et al. N. Engl. J. Med. (2004) pmid: 15118073
76. Paez JG, et al. Science (2004) pmid: 15118125
77. Pao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2004) pmid: 15329413
78. Yang JC, et al. Lancet Oncol. (2015) pmid: 25589191
79. Zehir A, et al. Nat. Med. (2017) pmid: 28481359
80. Bailey MH, et al. Cell (2018) pmid: 29625053
81. Bolton KL, et al. Nat Genet (2020) pmid: 33106634
82. Scheuermann JC, et al. Nature (2010) pmid: 20436459
83. Cho YS, et al. J. Biol. Chem. (2006) pmid: 16606617
84. Park UH, et al. J. Biol. Chem. (2011) pmid: 21047783
85. Inoue D, et al. J. Clin. Invest. (2013) pmid: 24216483
86. Abdel-Wahab O, et al. Cancer Cell (2012) pmid: 22897849
87. Br. J. Cancer (2013) pmid: 23736028
88. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
89. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
90. Xie M, et al. Nat. Med. (2014) pmid: 25326804
91. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
92. Severson EA, et al. Blood (2018) pmid: 29678827
93. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
94. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
95. Chabon JJ, et al. Nature (2020) pmid: 32269342
96. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
97. Kang MH, et al. Clin. Cancer Res. (2009) pmid: 19228717
98. Zhou H, et al. J. Med. Chem. (2012) pmid: 22747598
99. Zhou H, et al. J. Med. Chem. (2012) pmid: 22448988
100. Zhang YL, et al. World J. Gastroenterol. (2008) pmid: 18494061
101. Ni Chonghaile T, et al. Science (2011) pmid: 22033517
102. Lei X, et al. Acta Biochim. Biophys. Sin. (Shanghai) (2007) pmid: 17492131
103. Qian J, et al. Mol. Cancer Ther. (2009) pmid: 19139118
104. Shen H, et al. Biomed. Pharmacother. (2009) pmid: 18848758
105. Reinmuth N, et al. Lung Cancer (2008) pmid: 18450321
106. Elstrand MB, et al. Int. J. Gynecol. Pathol. (2009) pmid: 19620938
107. Postma C, et al. Cell. Oncol. (2007) pmid: 17429145
108. Biroccio A, et al. Am. J. Pathol. (2001) pmid: 11290547
109. Williams J, et al. Gynecol. Oncol. (2005) pmid: 15661210
110. Wong M, et al. Mol. Cancer Ther. (2012) pmid: 22302098
111. Environ. Mol. Mutagen. (2010) pmid: 20213841
112. Annunziata CM, et al. Clin. Cancer Res. (2007) pmid: 18006758
113. Kar R, et al. Cancer Biol. Ther. (2007) pmid: 17611399
114. Sillars-Hardebol AH, et al. J. Pathol. (2012) pmid: 22009326
115. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
116. Gao J, et al. Sci Signal (2013) pmid: 23550210
117. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
118. Bettegowda C, et al. Science (2011) pmid: 21817013
119. Yip S, et al. J. Pathol. (2012) pmid: 22072542
120. Sahm F, et al. Acta Neuropathol. (2012) pmid: 22588899
121. Jiao Y, et al. Oncotarget (2012) pmid: 22869205
122. Chan AK, et al. Mod. Pathol. (2014) pmid: 24030748
123. Lee CJ, et al. Brain Res. Mol. Brain Res. (2002) pmid: 12393275
124. Mensah AA, et al. Oncotarget (2015) pmid: 25671298
125. Grasso CS, et al. Ann. Oncol. (2015) pmid: 25735316
126. Ma X, et al. Nat Commun (2015) pmid: 25790293
127. Green MR, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25713363
128. Loeffler M, et al. Leukemia (2015) pmid: 25027518
129. Gervais C, et al. Leukemia (2008) pmid: 18528428
130. Haferlach T, et al. Leukemia (2009) pmid: 19194466
131. Petrij F, et al. J. Med. Genet. (2000) pmid: 10699051
132. Borrow J, et al. Nat. Genet. (1996) pmid: 8782817
133. Kao YC, et al. Genes Chromosomes Cancer (2017) pmid: 27537276
134. Hofvander J, et al. Mod. Pathol. (2020) pmid: 31932680
135. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
136. Joly MO, et al. Hum. Mutat. (2015) pmid: 25504677
137. Pritchard CC, et al. Nat Commun (2014) pmid: 25255306
138. Rosty C, et al. Fam. Cancer (2014) pmid: 25117503
139. McConechy MK, et al. Gynecol. Oncol. (2015) pmid: 25636458
140. Le et al., 2015; ASCO Abstract LBA100
141. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
142. Lipson EJ, et al. Clin. Cancer Res. (2013) pmid: 23169436
143. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
144. Ding L, et al. Nature (2008) pmid: 18948947
145. Negrini S, et al. Nat. Rev. Mol. Cell Biol. (2010) pmid: 20177397
146. Johannsdottir JT, et al. Anticancer Res. () pmid: 10470121
147. de la Chapelle A, et al. J. Clin. Oncol. (2010) pmid: 20516444
148. Popat S, et al. J. Clin. Oncol. (2005) pmid: 15659508
149. Chen G, et al. Zhongguo Fei Ai Za Zhi (2000) pmid: 20937204
150. Li F, et al. Cell (2013) pmid: 23622243
151. Wu H, et al. PLoS ONE (2011) pmid: 21720545
152. Edelbrock MA, et al. Mutat. Res. () pmid: 23391514
153. Berends MJ, et al. Am. J. Hum. Genet. (2002) pmid: 11709755
154. Warren JJ, et al. Mol. Cell (2007) pmid: 17531815
155. Geng H, et al. J. Biol. Chem. (2012) pmid: 22277660
156. Silva FC, et al. Sao Paulo Med J (2009) pmid: 19466295

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

157. Raevaara TE, et al. Gastroenterology (2005) pmid: 16083711
158. Kastrinos F, et al. Semin. Oncol. (2007) pmid: 17920897
159. Sehgal R, et al. Genes (Basel) (2014) pmid: 24978665
160. Fam. Cancer (2005) pmid: 16136383
161. Wimmer K, et al. Hum. Genet. (2008) pmid: 18709565
162. Wimmer K, et al. J. Med. Genet. (2014) pmid: 24737826
163. Scott RH, et al. Nat Clin Pract Oncol (2007) pmid: 17259933
164. Ripperger T, et al. Haematologica (2010) pmid: 20015892
165. Baris HN, et al. Pediatr Blood Cancer (2016) pmid: 26544533
166. Binkley MS, et al. Cancer Discov (2020) pmid: 33071215
167. Chowdhry S, et al. Oncogene (2013) pmid: 22964642
168. Abazeed ME, et al. Cancer Res. (2013) pmid: 23980093
169. Shibata T, et al. Cancer Res. (2010) pmid: 21062981
170. Bendavit G, et al. J. Biol. Chem. (2016) pmid: 27784786
171. Paik et al., 2019; ASCO Abstract 9085
172. Kim YR, et al. J. Pathol. (2010) pmid: 19967722
173. Shibata T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18757741
174. Sasaki H, et al. Int. J. Mol. Med. (2013) pmid: 23545629
175. Yang H, et al. Clin Lung Cancer (2011) pmid: 21663859
176. Ji L, et al. Int J Clin Exp Pathol (2014) pmid: 24695690
177. Hu XF, et al. Asian Pac. J. Cancer Prev. (2013) pmid: 24175806
178. Kawasaki Y, et al. BMC Cancer (2015) pmid: 25588809
179. Kawasaki Y, et al. Ann. Surg. Oncol. (2014) pmid: 24599410
180. Park JY, et al. Pathology (2012) pmid: 23172081
181. Wang XJ, et al. Carcinogenesis (2008) pmid: 18413364
182. Leinonen HM, et al. Adv. Cancer Res. (2014) pmid: 24974185
183. Kobayashi A, et al. Mol. Cell. Biol. (2004) pmid: 15282312
184. Sjöblom T, et al. Science (2006) pmid: 16959974
185. Kan Z, et al. Nature (2010) pmid: 20668451
186. Furukawa T, et al. Sci Rep (2011) pmid: 22355676
187. Martínez-Arribas F, et al. J. Cell. Biochem. (2006) pmid: 16552754
188. Martín-Garabato E, et al. Cancer Genomics Proteomics () pmid: 18820371
189. Wang Y, et al. EMBO Mol Med (2013) pmid: 24000153
190. Inoue A, et al. FEBS Lett. (2014) pmid: 24530524
191. Johnston JJ, et al. Am. J. Hum. Genet. (2010) pmid: 20451169
192. Gripp KW, et al. Am. J. Med. Genet. A (2011) pmid: 21910224
193. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
194. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
195. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
196. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
197. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
198. Xu L, et al. Mol. Med. (2001) pmid: 11713371
199. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
200. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
201. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
202. Hajdenberg et al., 2012; ASCO Abstract e15010
203. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
204. Moore et al., 2019; ASCO Abstract 5513
205. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
206. Oza et al., 2015; ASCO Abstract 5506
207. Lee J, et al. Cancer Discov (2019) pmid: 31315834
208. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
209. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
210. Kwok M, et al. Blood (2016) pmid: 26563132
211. Boudny M, et al. Haematologica (2019) pmid: 30975914
212. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704
213. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
214. Mogi A, et al. J. Biomed. Biotechnol. (2011) pmid: 21331359
215. Tekpli X, et al. Int. J. Cancer (2013) pmid: 23011884
216. Vignot S, et al. J. Clin. Oncol. (2013) pmid: 23630207
217. Maeng CH, et al. Anticancer Res. (2013) pmid: 24222160
218. Cortot AB, et al. Clin Lung Cancer (2014) pmid: 24169260
219. Itakura M, et al. Br. J. Cancer (2013) pmid: 23922113
220. Kim Y, et al. J. Clin. Oncol. (2014) pmid: 24323028
221. Dong ZY, et al. Clin. Cancer Res. (2017) pmid: 28039262
222. Seo JS, et al. Genome Res. (2012) pmid: 22975805
223. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
224. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
225. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
226. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
227. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
228. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
229. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
230. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
231. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
232. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
233. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
234. Lalloo F, et al. Lancet (2003) pmid: 12672316
235. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
236. Wu YL, et al. Lancet Oncol. (2014) pmid: 24439929
237. Passaro et al., 2019; ELCC Abstract 1150
238. Audet et al., 2013; ASCO Abstract 6041
239. Lau SC, et al. Clin Lung Cancer (2019) pmid: 31178389
240. Paz-Ares L, et al. Ann. Oncol. (2017) pmid: 28426106
241. Thongprasert S, et al. Lung Cancer Manag (2019) pmid: 31807143
242. Januszewski et al., 2018; IASLC WCLC Abstract P1.13-17
243. Suzuki et al., 2018; IASLC WCLC Abstract P1.01-92
244. Chang et al., 2018; IASLC WCLC Abstract P1.01-11
245. Llinás-Quintero N, et al. Case Rep Oncol Med (2019) pmid: 31637072
246. Miller VA, et al. Lancet Oncol. (2012) pmid: 22452896
247. Chen X, et al. Lung Cancer (2013) pmid: 23664448
248. Katakami N, et al. J. Clin. Oncol. (2013) pmid: 23816963
249. Landi L, et al. Clin Lung Cancer (2014) pmid: 25242668
250. De Grève J, et al. Lung Cancer (2015) pmid: 25682316
251. Yang JC, et al. Lancet Oncol. (2015) pmid: 26051236
252. Horn L, et al. Lung Cancer (2017) pmid: 29110849
253. Yamamoto N, et al. Adv Ther (2020) pmid: 31863283
254. Soria JC, et al. Lancet Oncol. (2015) pmid: 26156651
255. Dziadziuszko R, et al. J Thorac Oncol (2019) pmid: 30825613
256. Lai WV, et al. Eur. J. Cancer (2019) pmid: 30685684
257. Greulich H, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22908275
258. Gow CH, et al. J Thorac Oncol (2015) pmid: 26134234
259. Mazières J, et al. Ann. Oncol. (2016) pmid: 26598547
260. Mazières J, et al. J. Clin. Oncol. (2013) pmid: 23610105
261. De Grève J, et al. Lung Cancer (2012) pmid: 22325357
262. Li BT, et al. Lung Cancer (2015) pmid: 26559459
263. Costa DB, et al. J Thorac Oncol (2016) pmid: 26964772
264. Yuan B, et al. Front Oncol (2020) pmid: 32477948
265. Fang W, et al. Oncologist (2019) pmid: 31748336
266. Schuler M, et al. Ann. Oncol. (2016) pmid: 26646759
267. Rizvi et al., 2019; ASCO Abstract 9016
268. Socinski et al., 2019; ESMO Abstract LBA83
269. Herbst RS, et al. N Engl J Med (2020) pmid: 32997907
270. Chen YT, et al. Front Oncol (2019) pmid: 31921683
271. Nie et al., 2020; WCLC Abstract OA07.03
272. West H, et al. Lancet Oncol. (2019) pmid: 31122901
273. Barlesi et al., 2018; ESMO Abstract LBA54
274. Rittmeyer A, et al. Lancet (2017) pmid: 27979383
275. Smith et al., 2016; ASCO Abstract 9028
276. Fehrenbacher L, et al. Lancet (2016) pmid: 26970723
277. Pietras et al., 2018; WCLC Abstract P1.04-3
278. Felip E, et al. Lancet (2021) pmid: 34555333
279. Rodriguez-Abreu et al., 2020; ASCO Abstract 9503
280. Sezer A, et al. Lancet (2021) pmid: 33581821
281. Shim et al., 2020; ESMO Abstract 1269P
282. Wu YL, et al. Lancet Oncol. (2017) pmid: 28958502
283. Opsomer RJ, et al. Acta Urol Belg (1985) pmid: 2986437
284. Wu et al., 2018; WCLC abstract MA26.11
285. Ramalingam SS, et al. Ann. Oncol. (2016) pmid: 26768165
286. Yu HA, et al. Lung Cancer (2017) pmid: 29191595
287. Reckamp KL, et al. Cancer (2014) pmid: 24501009
288. Jänne PA, et al. Clin. Cancer Res. (2011) pmid: 21220471
289. van Geel RMJM, et al. Br. J. Cancer (2020) pmid: 32147669
290. Jänne PA, et al. J Thorac Oncol (2016) pmid: 26899759
291. Subramanian et al., 2020; ESMO Abstract 1399P
292. Andre et al., 2021; ASCO GI Abstract 9
293. Oaknin A, et al. JAMA Oncol (2020) pmid: 33001143
294. Berton et al., 2021; ASCO Abstract 2564
295. Andre et al., 2021; ESMO GI Abstract SO-9
296. Paz-Ares L, et al. Ann. Oncol. (2020) pmid: 32209338
297. Faivre-Finn C, et al. J Thorac Oncol (2021) pmid: 33476803
298. Planchard D, et al. Ann. Oncol. (2020) pmid: 32201234
299. Rizvi NA, et al. JAMA Oncol (2020) pmid: 32271377
300. Johnson et al., 2021; WCLC Abstract PL02.01
301. Antonia SJ, et al. J Thorac Oncol (2019) pmid: 31228626
302. Garassino MC, et al. Lancet Oncol. (2018) pmid: 29545095
303. Garassino et al., 2018; WCLC Abstract P1.01-21
304. Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771
305. Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613
306. Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888
307. Yang JJ, et al. Br. J. Cancer (2017) pmid: 28103612
308. Lee CK, et al. J. Natl. Cancer Inst. (2017) pmid: 28376144
309. Nakagawa K, et al. Lancet Oncol. (2019) pmid: 31591063
310. Stinchcombe TE, et al. JAMA Oncol (2019) pmid: 31393548
311. Shepherd FA, et al. N. Engl. J. Med. (2005) pmid: 16014882
312. Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314
313. Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926
314. Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809
315. Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

316. Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826
317. Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556
318. Wang J, et al. Int. J. Cancer (2019) pmid: 30255937
319. Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831
320. Yoshioka H, et al. Ann. Oncol. (2019) pmid: 31553438
321. Fukuoka M, et al. J. Clin. Oncol. (2011) pmid: 21670455
322. Noronha V, et al. J. Clin. Oncol. (2019) pmid: 31411950
323. Hosomi Y, et al. J. Clin. Oncol. (2020) pmid: 31682542
324. Sutiman N, et al. J Thorac Oncol (2017) pmid: 27908825
325. Gibbons DL, et al. J Thorac Oncol (2016) pmid: 27198414
326. Borghaei H, et al. N. Engl. J. Med. (2015) pmid: 26412456
327. Brahmer J, et al. N. Engl. J. Med. (2015) pmid: 26028407
328. Rizvi NA, et al. Lancet Oncol. (2015) pmid: 25704439
329. Lind et al., 2020; BTOG Abstract 113
330. Paz-Ares et al., 2019; ESMO Immuno-Oncology Congress Abstract LBA3
331. Rizvi NA, et al. J. Clin. Oncol. (2016) pmid: 27354481
332. Forde et al., 2021; AACR Abstract CT003
333. Diab A, et al. Cancer Discov (2020) pmid: 32439653
334. Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359
335. Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755
336. Kim et al., 2021; DOI: 10.1200/PO.20.00296
337. Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012
338. Herbst et al., 2020; ASCO Abstract LBA5
339. Kenmotsu et al., 2021; ESMO Abstract LBA44
340. Soo et al., 2021; ESMO Abstract VP3-2021
341. Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298
342. Mok TSK, et al. Lancet (2019) pmid: 30955977
343. Brahmer et al., 2020; ESMO LBA51
344. Garon EB, et al. J. Clin. Oncol. (2019) pmid: 31154919
345. Aguilar EJ, et al. Ann. Oncol. (2019) pmid: 31435660
346. Gadgeel S, et al. J. Clin. Oncol. (2020) pmid: 32150489
347. Paz-Ares L, et al. N. Engl. J. Med. (2018) pmid: 30280635
348. Paz-Ares L, et al. J Thorac Oncol (2020) pmid: 32599071
349. Paz-Ares et al., 2019; ESMO Abstract LBA80
350. Garassino et al., 2020; ASCO Abstract 9521
351. Doherty et al., 2018; WCLC Abstract P1.01-16
352. Herbst RS, et al. Lancet (2016) pmid: 26712084
353. Powell et al., 2019; ESMO Abstract 1483PD
354. Mansfield et al., 2019; ESMO Abstract 1482O
355. Goldberg SB, et al. Lancet Oncol. (2016) pmid: 27267608
356. Spicer et al., 2020; SITC Abstract 362
357. Gubens MA, et al. Lung Cancer (2019) pmid: 30885353
358. Niu et al., 2020; ESMO Abstract 1410P
359. Gray JE, et al. Clin. Cancer Res. (2019) pmid: 31409616
360. Brose et al., 2019; DOI: 10.1200/JCO.2019.37.8_suppl.16
361. Ramalingam SS, et al. Cancer (2021) pmid: 34478166
362. Barlesi F, et al. Lancet Oncol (2018) pmid: 30262187
363. Park K, et al. J Thorac Oncol (2021) pmid: 33845211
364. Park K, et al. Lung Cancer (2021) pmid: 33636453
365. Verschraegen CF, et al. J Immunother Cancer (2020) pmid: 32907924
366. Galffy et al., 2020; SITC Abstract 281
367. Shafique M, et al. Clin Cancer Res (2021) pmid: 33820783
368. Tfayli A, et al. Cancer Med (2020) pmid: 32991781

Electronically signed by J. Keith Killian, M.D. | 23 January 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531